{"organizations": [], "uuid": "d68773a02f408f695635e6e2fc57afff57c87c6d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180122.html", "section_title": "Archive News &amp; Video for Monday, 22 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/buzz-vical-falls-as-herpes-vaccine-fails/buzz-vical-falls-as-herpes-vaccine-fails-late-stage-trial-idUSL4N1PH46X", "country": "US", "domain_rank": 408, "title": "BUZZ-Vical: Falls as herpes vaccine fails late-stage trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T21:20:00.000+02:00", "replies_count": 0, "uuid": "d68773a02f408f695635e6e2fc57afff57c87c6d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/buzz-vical-falls-as-herpes-vaccine-fails/buzz-vical-falls-as-herpes-vaccine-fails-late-stage-trial-idUSL4N1PH46X", "ord_in_thread": 0, "title": "BUZZ-Vical: Falls as herpes vaccine fails late-stage trial", "locations": [], "entities": {"persons": [{"name": "h.c. wainwright", "sentiment": "none"}, {"name": "akankshita mukhopadhyay", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}], "organizations": [{"name": "astellas pharma", "sentiment": "none"}, {"name": "vical", "sentiment": "none"}, {"name": "tr", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "** Drugmaker’s shares fall 27.81 pct to $1.35 - top pct loser among Nasdaq-listed stocks premarket\n** Tokyo-listed Astellas Pharma and Vical said its herpes vaccine, ASP0113, did not meet the main and secondary goals in a late-stage study\n** Companies said the vaccine did not demonstrate a significant improvement in overall survival of patients under the trial program\n** ASP0113, a vaccine to prevent herpes reactivation in stem cell transplant recipients, has “orphan” drug status in the United States and Europe\n** Brokerage H.C. Wainwright cuts PT to $5 from $6; median PT is $5.10 - TR data\n** Up to Friday’s close, stock had fallen 15.4 pct in the past twelve months (Reporting by Akankshita Mukhopadhyay in Bengaluru)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-22T21:20:00.000+02:00", "crawled": "2018-01-23T18:03:30.004+02:00", "highlightTitle": ""}